On November 4, 2025, the National Medical Products Administration (NMPA) officially released a revised version of the Good Manufacturing Practice (GMP) for medical devices. This marks the first significant update since the 2014 edition and is positioned as a transformative step toward enhancing regulatory oversight, product safety, and quality across China’s rapidly evolving medtech sector set to take effect on November 1, 2026, the new GMP framework incorporates modern regulatory practices, risk management principles, and digital innovation, aiming to elevate the industry’s global competitiveness and safety standards.
CHINA’S REVISED GMP FOR MEDICAL DEVICES TAKES EFFECT IN 2026
The revision supports the implementation of national policy objectives outlined in the 2024 State Council Opinion No.53 on reforming drug and device regulation to promote high-quality development in the pharmaceutical and medical device industries.
It aligns with:
- International best practices in Quality Management Systems (QMS)
- Lifecycle-based risk management
- Embracing digital and intelligent manufacturing systems
WHAT’S NEW IN THE REVISED GOOD MANUFACTURING PRACTICE FOR MEDICAL DEVICES
The revised GMP introduces 15 chapters and 132 articles, including three newly added chapters:
1. Quality Assurance
Defines structured frameworks for ensuring continuous product quality and consistency throughout the manufacturing lifecycle.
2. Validation and Verification (V&V)
Emphasizes the need for robust and documented processes to ensure the reliability of critical manufacturing operations.
3. Contract Manufacture and Outsourcing
Clarifies responsibilities for manufacturers engaging with third-party vendors, contract manufacturers, and external service providers.
Transition Timeline
Milestone | Date |
Revision Release | November 4, 2025 |
Effective Date | November 1, 2026 |
Manufacturers have nearly 12 months to align internal systems, retrain staff, and revise documentation to comply with the updated GMP requirements.
WHAT SHOULD MANUFACTURERS DO NOW?
- Conduct a gap assessment between current QMS and the new GMP requirements.
- Update SOPs, technical files, QA processes, and validation plans.
- Ensure supplier and contract partner audits are enhanced to reflect new responsibilities.
- Invest in digital tools and automated systems where feasible.
- Initiate internal training programs to educate staff on new obligations and expectations.
SUMMARY
China’s revised GMP framework represents a major leap forward in aligning its regulatory system with international standards while accommodating modern manufacturing realities. For manufacturers, this is not just a compliance obligation, it is a strategic opportunity to optimize operations, strengthen market credibility, and future-proof their business in one of the world’s largest medical device markets. For more information or support on implementing these changes, manufacturers are encouraged to consult local regulatory experts or refer to the official NMPA website